Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical United States Advisory Committees

Sarepta's Additional Data Doesn't Sway FDA On Eteplirsen

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Agency reviewers raise more concerns about efficacy of proposed Duchenne muscular dystrophy treatment despite new information.

You may also be interested in...



Rare Disease Patients: Placebo Controls, Sham Surgeries Not Appropriate For Gene Therapy Trials

Advocates also worry that long follow-up times could prevent participation in future clinical trials.

Rare Disease Cures Accelerator Expected To Drive Lots Of Development – Eventually

Sarepta Eyes Patient Outcomes To Boost Exondys 51's European Review

EMA and payers want to know more about daily life improvements from US FDA-approved Duchenne muscular dystrophy treatment.

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Pink Sheet

Topics

Related Companies

Tags:
BioPharmaceutical United States Advisory Committees
Latest Headlines

Medicare Price Negotiation: Special Treatment For ‘Novel Technologies’ On PhRMA’s Advocacy Agenda

As Quantity Of Cannabis IND Applications Grows, US FDA Has ‘Quality Considerations’ Guidance

ABPI President Steps Down Amid Novo Nordisk Code Of Practice Breach

EU Fees Revision A ‘Once-In-A-Generation’ Chance To Solve Resource Challenges

See All
UsernamePublicRestriction

Register

PS079338

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By